Autologous Platelet Concentrates in the Management of Medication-Related Osteonecrosis of the Jaw: A Systematic Review
Ferreira F., Faria C., Pozza DH.
Systematic Review, published in Medicina (Kaunas) (2025) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Systematic Review
- Journal
- Medicina (Kaunas) (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40870542
- PMCID
- PMC12388798
- DOI
- 10.3390/medicina61081496
- Citations
- 1
Abstract (original English)
Background and Objectives : Medication-related osteonecrosis of the jaw (MRONJ) is a challenging condition linked to antiresorptive and antiangiogenic medications. Their complex pathophysiology and resistance to standard treatments have led researchers to explore adjunctive therapies. This systematic review evaluated the effectiveness of autologous platelet concentrates-namely platelet-rich plasma (PRP) and platelet-rich fibrin (PRF)-in promoting healing, bone regeneration, and symptom relief in MRONJ patients. Materials and Methods : A systematic literature search was conducted using PubMed, Scopus, and Web of Science for studies that assessed the use of PRP or PRF in MRONJ management. The risk of bias and study quality were evaluated using ROB-2 and ROBINS-I tools. Results : A total of 24 studies were included: seven on PRP and 17 on PRF. Reported complete mucosal healing rates ranged from 33% to 100% for PRP and from 36% to 100% for PRF. Although two randomized controlled trials and one prospective observational study found no statistically significant advantage of PRF over conventional surgical treatments, most studies indicated positive outcomes. Overall, the methodological quality varied, with several studies showing moderate-to-high risk of bias. Conclusions : Platelet concentrates can add benefits to traditional MRONJ treatments. The current evidence suggests that integ
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.